TR3 Modulates Platinum Resistance in Ovarian Cancer

Andrew J. Wilson1, Annie Y. Liu1, Joseph Roland2, Oluwafunmilayo B. Adebayo1, Sarah A. Fletcher3, James C. Slaughter3, Jeanette Saskowski1, Marta A. Crispens1,5, Howard W. Jones III1,5, Samuel James4, Oluwole Fadare4,5, and Dineo Khabele1,5

Abstract

In metastatic ovarian cancer, resistance to platinum chemotherapy is common. Although the orphan nuclear receptor TR3 (nur77/NR4A1) is implicated in mediating chemotherapy-induced apoptosis in cancer cells, its role in ovarian cancer has not been determined. In an ovarian cancer tissue microarray, TR3 protein expression was elevated in stage I tumors, but downregulated in a significant subset of metastatic tumors. Moreover, TR3 expression was significantly lower in platinum-resistant tumors in patients with metastatic disease, and low TR3 staining was associated with poorer overall and progression-free survival. We have identified a direct role for TR3 in cisplatin-induced apoptosis in ovarian cancer cells. Nucleus-to-cytoplasm translocation of TR3 was observed in cisplatin-sensitive (OVCAR8, OVCAR3, and A2780CP20) ovarian cancer cells. Immunofluorescent analyses showed clear overlap between TR3 and mitochondrial Hsp60 in cisplatin-treated cells, which was associated with cytochrome c release. Ovarian cancer cells with stable shRNA- or transient siRNA-mediated TR3 down-regulation displayed substantial reduction in cisplatin effects on apoptotic markers and cell growth in vitro and in vivo. Mechanistic studies showed that the cisplatin-induced cytoplasmic TR3 translocation required for apoptosis induction was regulated by JNK activation and inhibition of Akt. Finally, cisplatin resistance was partially overcome by ectopic TR3 overexpression and by treatment with the JNK activator anisomycin and Akt pathway inhibitor, wortmannin. Our results suggest that disruption of TR3 activity, via downregulation or nuclear sequestration, likely contributes to platinum resistance in ovarian cancer. Moreover, we have described a treatment strategy aimed at overcoming platinum resistance by targeting TR3. Cancer Res; 73(15): 4758–69. ©2013 AACR.

Introduction

Ovarian cancer is the most lethal gynecologic malignancy and the vast majority of epithelial ovarian malignancies present as biologically aggressive, metastatic disease (1, 2). The high incidence of relapse following standard platinum-based therapy indicates that there is an urgent need for new treatment strategies and novel insight into mechanisms of platinum resistance. As most high-grade ovarian cancers harbor mutations in TP53 (3), identifying antitumor effectors that act independently of p53 is an important goal.

TR3 (also known as nur77 and NR4A1) has emerged as a major regulator of cancer cell survival and an attractive therapeutic target (4). TR3 is a member of the NR4A family of nuclear receptors, and mediates apoptosis in various cancer cell types in response to a wide range of chemotherapeutic agents. Known mechanisms of TR3-induced apoptosis include p53-independent nuclear-cytoplasmic translocation, leading to cytochrome c release in response to various proapoptotic drugs (5–11), or upregulation of proapoptotic genes and/or downregulation of antiapoptotic genes (12–14). Nuclear export of TR3 is known to involve specific changes in its phosphorylation status, such as N-terminal serine phosphorylation by JNK and loss of Akt-mediated phosphorylation on serine 351 (15). At the mitochondria, TR3 binds Bcl-2, which induces a conformational change such that Bcl-2 assumes a proapoptotic function (9). Apoptosis mediated at least partly through TR3 activity has been reported in an ovarian-derived teratocarcinoma cell line, Pa-1 (5). However, it is unknown whether TR3 mediates apoptotic effects of established chemotherapeutic agents such as cisplatin in ovarian cancer cells of epithelial origin.

Despite the clear proapoptotic role for TR3 identified in chemotherapy-treated cancer cells, accumulated evidence indicates that it may play a more complex role in tumorigenesis. TR3 expression is also induced by mitogenic factors in the...
absence of apoptosis in various cancer cell types and is upregulated in some solid epithelial tumors (11, 16–19). In contrast, TR3 is downregulated in some metastatic solid tumors (17, 20) and TR3-mediated suppression of colon cancer tumorigenesis has been recently reported (14, 21). The Cancer Genome Atlas (TCGA) data show that TR3 mRNA expression is detected in ovarian tumors, although no significant alterations in the TR3 gene, such as mutation, amplification, or promoter methylation, are present in these tumors (3). There have been no previous reports measuring TR3 protein expression in epithelial ovarian tumors.

To identify possible roles of TR3 in ovarian cancer, and to relate TR3 protein expression to clinical outcomes, we first determined its expression in a tissue microarray (TMA) generated from tumor samples from 209 patients with ovarian cancer. We showed an association between low TR3 expression, resistance to platinum chemotherapy, and survival indices. Then, we identified a functional link between TR3 and cisplatin-mediated apoptosis in ovarian cancer cells. Collectively, our results suggest that TR3 is an important regulator of ovarian cancer cell apoptosis, and that low TR3 expression is associated with drug resistance. This study has implications for future treatment strategies to overcome platinum resistance in ovarian cancer.

### Materials and Methods

**Cell culture, chemicals, and plasmids**

Growth of the epithelial ovarian cancer cell lines SKOV3, OVCAR3, NCI/ADR-RES, OVCAR5, and OVCAR8, well-characterized as part of the National Cancer Institute (NCI) 60 Cancer Panel (22–24), have been described previously (25). A2780 PAR and A2780 CP20 cells were kind gifts from Prof. Anil Sood (MD Anderson Cancer Center, Houston, TX; ref. 26). Growth of normal human ovarian surface epithelium (HOSE) cells has also been described (25). All cell lines were used within 6 months of receipt from the aforementioned cell line banks and all were tested negative for mycoplasma. The cells were treated with the DNA-damaging agents, cisplatin and doxorubicin (both from Sigma Chemical Co.), the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA; kind gift from Dr. Edward Holson, Stanley Center for Psychiatric Research; Broad Institute, Cambridge, MA), the nuclear export inhibitor, leptomycin B (Sigma Chemical Co.), the JNK inhibitor, SP600125 (Enzo Life Sciences), the PI3K inhibitor, wortmannin (Enzo Life Sciences), and the JNK activator, anisomycin (both from Sigma Chemical Co.). The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA; kind gift from Dr. Edward Holson, Stanley Center for Psychiatric Research; Broad Institute, Cambridge, MA), the nuclear export inhibitor, leptomycin B (Sigma Chemical Co.), the JNK inhibitor, SP600125 (Enzo Life Sciences), the PI3K inhibitor, wortmannin (Enzo Life Sciences), and the JNK activator, anisomycin (both from Sigma Chemical Co.). These cells were transfected (Lipofectamine 2000, Invitrogen) with predesigned pGFP-V-RS shRNA HuSH-29 plasmids targeting human TR3 (ShTR3) or control, scrambled shRNA (ShScr) on the same vector background (Origene). Additional details regarding selection, characterization, and maintenance of clones are in Supplementary Methods. For transient TR3 knockdown, OVCAR3 cells were transfected with ON-TARGETplus nontargeting (NT) or TR3-targeting siRNA duplexes (Thermo Fisher Scientific, Inc.) using RNAiMAX transfection reagent (Invitrogen).

**Immunofluorescence**

Cells were grown, fixed, permeabilized, and stained with anti-NR4A1/3, anti-Hsp60, anti-cytochrome c, anti-Bcl-2, and anti-DDK (FLAG) primary antibodies as previously described (7). Additional details regarding primary and secondary antibodies, and for cell counts, are provided in Supplementary Methods. Images were acquired and analyzed as previously described (27).

**Western blotting**

Whole-cell protein isolation, subcellular fractionation, Western blotting, and signal detection were conducted as described previously (25, 28) to detect anti-TR3/mar77, anti-Nurr1/NR4A2, anti-NOR1/NR4A3, anti-Parp, anti-caspase-3, anti-β-actin, anti-histone H3, anti-Bcl-2, anti-DDK (FLAG), anti-phospho-JNK (Thr183/Tyr185), anti-phospho-Akt (Ser473), and anti-α-tubulin primary antibodies. Additional details are provided in Supplementary Methods. Coimmunoprecipitation experiments with anti-TR3 on lysates normalized for TR3 expression were conducted as previously described (28).

**Quantitative real-time reverse transcriptase PCR**

RNA isolation and cDNA synthesis were conducted as previously described (29). Levels of mRNA expression for TR3 and NR4A2 were determined using TaqMan gene expression assays. Additional details are provided in Supplementary Methods.

**Sulfurhodamine B assays**

Sulfurhodamine B (SRB) growth assays were conducted as previously described (29, 30). Effects on cell growth were measured 72 hours after addition of drugs. Absorbance was measured at 510 nm using a SpectraMax M5 spectrophotometer (Molecular Devices) in the High-Throughput Screening Core of the Vanderbilt Institute of Chemical Biology (Nashville, TN).

**Xenograft assays**

Four- to five-week-old female athymic Nude-Foxn1nu mice were purchased from Harlan Laboratories. For this subcutaneous xenograft model, 5 × 10^6 OVCAR8 ShScr or ShTR3 cells in 200 μL of a PBS/Matrigel (BD Biosciences) mixture (1:1 v/v) were injected subcutaneously into the right flank. After the tumors reached approximately 200 mm^3 in volume, mice were randomized and treated with cisplatin (5 mg/kg weekly) or vehicle control (PBS) for 3 weeks before euthanasia and necropsy (30). Tumor volume was calculated weekly from tracings of the smallest (SD) and largest diameters (LD) using the formula: volume = (LD × SD)² × π/6 (28). Experiments conducted received prior approval from the

---

Published OnlineFirst May 29, 2013; DOI: 10.1158/0008-5472.CAN-12-4560
Wilson et al.

Vanderbilt University Institutional Animal Use and Care Committee, and all animals were maintained in accordance to guidelines of the American Association of Laboratory Animal Care.

Case selection and TMA generation

Institutional Review Board approval for the tissue studies was obtained at Vanderbilt University Medical Center (VUMC). To compare TR3 expression in normal and neoplastic epithelium, we obtained deidentified tissue from human epithelial ovarian tumors with serous histology and normal human ovarian samples from the Vanderbilt Translational Pathology Shared Resource. For the TMA, 209 patients diagnosed with ovarian cancer at VUMC between 1994 and 2004 had evaluable paraffin tissue blocks. Additional details regarding generation of the TMA, recording of patient clinical data, and for definitions of overall and progression-free survival (PFS) and platinum sensitivity, are provided in Supplementary Methods. Tumor stage and grade was assigned on the basis of the International Federation of Gynecology and Obstetrics system (31). Clinical data relating to tumor stage, grade, histology, and platinum sensitivity of patient tumors are summarized in Table 1.

Immunohistochemistry

Tissue fixation, processing, and sectioning methods have been previously described (32). Hematoxylin and eosin staining for histology and immunostaining for anti-TR3/NR4A1, anti-pan-cytokeratin, anti-cleaved caspase-3, and anti-mib-1/Ki67 primary antibodies were conducted as described (32). Additional details for these antibodies, and for cell counts in ovarian xenografts, are provided in Supplementary Methods. For the TMAs, semiquantitative measurement of TR3 expression in tumors was conducted using the automated Ario1 SL-50 Platform (Molecular Devices LLC). Additional details are provided in Supplementary Methods.

Statistical analysis

For in vitro experiments, values shown were the mean ± SD of 3 independent experiments with P < 0.05 relative to appropriate controls considered to be statistically significant (Student t test). In our mouse experiments, differences between groups were determined by Mann–Whitney U test. For TMA analyses, Kaplan–Meier curves were used to analyze PFS and OS. Survival curves were compared using the Cox proportional hazards model. The likelihood ratio test was used to assess statistical significance. Differences in TR3 expression related to tumor stage (stage I vs. II/III/IV), grade (grade 1 vs. 2/3), and platinum sensitivity or resistance were determined by Mann–Whitney test.

Results

TR3 expression is heterogeneous in ovarian cancer cells

While TR3 exerts diverse effects in cancer cells, such as mediating apoptosis induction by multiple chemotherapeutic agents (5–11) or promoting cell growth in response to mitogenic stimuli (11), its role in ovarian cancer cell biology is unknown. Data extracted from publicly available databases confirmed that TR3 mRNA expression is detected at variable levels in primary ovarian tumor samples (3, 33) and the NCI60 panel of ovarian cancer cell lines (22–24).

To determine protein expression levels of TR3, we examined 5 ovarian cancer cell lines represented in the NCI60 panel. As shown in Fig. 1A, TR3 expression was heterogeneous, with relatively high expression levels in NCI/ADR-RES, OVCAR8, and OVCAR5 cells. Low TR3 expression was observed in SKOV3 and OVCAR5 cells. We then confirmed that TR3 was detected by immunohistochemical staining in ovarian tumors (Supplementary Fig. S1). Prominent nuclear TR3 expression was observed in areas of tumor tissue with correspondingly high levels of the epithelial marker, pan-cytokeratin, and the

Table 1. Clinical data for the 209 patients with ovarian cancer whose tumors were used to generate a TMA

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Measure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age at diagnoses, y</td>
<td>56.76</td>
</tr>
<tr>
<td>Tumor stage</td>
<td></td>
</tr>
<tr>
<td>IA</td>
<td>29 (13.9%)</td>
</tr>
<tr>
<td>IB</td>
<td>2 (1.0%)</td>
</tr>
<tr>
<td>IC</td>
<td>21 (10.0%)</td>
</tr>
<tr>
<td>IIA</td>
<td>2 (1.0%)</td>
</tr>
<tr>
<td>IIIB</td>
<td>1 (0.5%)</td>
</tr>
<tr>
<td>IIC</td>
<td>6 (2.9%)</td>
</tr>
<tr>
<td>IIIA</td>
<td>5 (2.4%)</td>
</tr>
<tr>
<td>IIIB</td>
<td>6 (2.9%)</td>
</tr>
<tr>
<td>IIIC</td>
<td>107 (51.2%)</td>
</tr>
<tr>
<td>IV</td>
<td>21 (10.0%)</td>
</tr>
<tr>
<td>Unstaged</td>
<td>5 (2.4%)</td>
</tr>
<tr>
<td>Unknown stage</td>
<td>4 (1.9%)</td>
</tr>
<tr>
<td>Platinum sensitive</td>
<td>86 (41.1%)</td>
</tr>
<tr>
<td>Platinum resistant</td>
<td>43 (20.6%)</td>
</tr>
<tr>
<td>Grade</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>38 (18.2%)</td>
</tr>
<tr>
<td>2</td>
<td>50 (23.9%)</td>
</tr>
<tr>
<td>3</td>
<td>108 (51.7%)</td>
</tr>
<tr>
<td>Unknown grade</td>
<td>13 (6.2%)</td>
</tr>
<tr>
<td>Histology</td>
<td></td>
</tr>
<tr>
<td>Epithelial</td>
<td>202 (96.7%)</td>
</tr>
<tr>
<td>Serous/papillary</td>
<td>140 (67.0%)</td>
</tr>
<tr>
<td>Endometrioid</td>
<td>27 (12.9%)</td>
</tr>
<tr>
<td>Mucinous</td>
<td>15 (7.2%)</td>
</tr>
<tr>
<td>Clear cell</td>
<td>9 (4.3%)</td>
</tr>
<tr>
<td>Mixed</td>
<td>6 (2.9%)</td>
</tr>
<tr>
<td>Other epithelial</td>
<td>5 (2.4%)</td>
</tr>
<tr>
<td>Other</td>
<td>7 (3.3%)</td>
</tr>
<tr>
<td>PFS, y</td>
<td>2.64 [± 2.13]</td>
</tr>
<tr>
<td>OS, y</td>
<td>3.33 [± 2.81]</td>
</tr>
</tbody>
</table>

NOTE: Values in round parentheses represent the percentage of the total (209) patients. For PFS and OS, numbers are mean [± SD].

4760 Cancer Res; 73(15) August 1, 2013 Cancer Research

Published OnlineFirst May 29, 2013; DOI: 10.1158/0008-5472.CAN-12-4560

Downloaded from cancerres.aacrjournals.org on July 22, 2017. © 2013 American Association for Cancer Research.
proliferation marker, Ki67. TR3 expression was also detected in
the single layer of cytokeratin-positive epithelial cells in normal
ovary (Supplementary Fig. S1), consistent with its abundant
expression in cells derived from normal HOSE (Fig. 1A).

Low TR3 expression in a subset of metastatic human
ovarian cancers is associated with platinum resistance
and reduced survival

To investigate the relationship between TR3 expression
in ovarian tumors and clinical outcomes, we determined the
percentage of TR3-positive tumor cells in each section of our
TMA. As all cells positive for TR3 within the tumor displayed
nuclear staining, with only a small subset of tumors (10/209)
containing cells displaying both nuclear and cytoplasmic
staining, counts were based on nuclear TR3 expression. TR3
expression for each tumor and associated clinical data are
shown in Supplementary Table S1. The median TR3 positivity
in these tumors was 72.1%. No significant differences were
observed in TR3 expression in the epithelial tumor subtypes
(Supplementary Fig. S2). Because the majority of epithelial
tumors were of papillary serous histology (140/202), and only
relatively small numbers of other histologic classes were
represented, we chose to restrict subsequent analyses to serous
tumors.

As shown in Fig. 1B and C, a high percentage of epithelial
cells in early-stage (I) serous tumors displayed TR3 expres-
sion. In contrast, a large subset of late-stage, metastatic
serous tumors showed significantly lower TR3 expression.
Lower TR3 nuclear staining was also associated with higher
grade tumors (Fig. 1B), with reduced overall and disease-free
survival (Fig. 1C) and, strikingly, with platinum resistance
(Fig. 1B). We then compared our data with results extracted
from publicly available ovarian cancer microarray databases,
TCGA (3) and Yoshihara and colleagues (33). TCGA data
indicate that 70% (186/268) of ovarian tumors show reduced
TR3 mRNA expression levels compared with normal tissue,
consistent with our results. However, the TCGA data dis-
played no significant association between TR3 mRNA
expression and platinum resistance or survival (Supplemen-
tary Fig. S3A and S3B). In contrast, a significant association
between low TR3 mRNA expression and reduced PFS, but
not overall survival, was shown in the Yoshihara dataset at
top/bottom 20%, 35%, and 50% cutoffs (Supplementary Fig.
S3C and S3D).

Cisplatin induces TR3 expression in ovarian cancer cells

As shown in Fig. 1B and C, a high percentage of epithelial
cells in early-stage (I) serous tumors displayed TR3 expres-
sion. In contrast, a large subset of late-stage, metastatic
serous tumors showed significantly lower TR3 expression.
Lower TR3 nuclear staining was also associated with higher
grade tumors (Fig. 1B), with reduced overall and disease-free
survival (Fig. 1C) and, strikingly, with platinum resistance
(Fig. 1B). We then compared our data with results extracted
from publicly available ovarian cancer microarray databases,
TCGA (3) and Yoshihara and colleagues (33). TCGA data
indicate that 70% (186/268) of ovarian tumors show reduced
TR3 mRNA expression levels compared with normal tissue,
consistent with our results. However, the TCGA data dis-
played no significant association between TR3 mRNA
expression and platinum resistance or survival (Supplemen-
tary Fig. S3A and S3B). In contrast, a significant association
between low TR3 mRNA expression and reduced PFS, but
not overall survival, was shown in the Yoshihara dataset at
top/bottom 20%, 35%, and 50% cutoffs (Supplementary Fig.
S3C and S3D).
However, no direct functional link between endogenous TR3 and platinum response in ovarian cancer cells has been previously shown. To determine the role of endogenous TR3 in cisplatin-induced growth inhibition and apoptosis, we selected 3 ovarian cancer cell lines with relatively high levels of basal TR3 expression (OVCAR8, NCI/ADR-RES, and OVCAR3) for further study (Fig. 1A). SRB cell growth experiments showed that NCI/ADR-RES cells were resistant to cisplatin (Fig. 2A), consistent with previous observations in these multidrug-resistant cells (27). NCI/ADR-RES cells are a derivative of OVCAR8 cells (23), which were more sensitive to cisplatin than NCI/ADR-RES and OVCAR3 cells (Fig. 2A). A similar pattern of effect across the cell lines was observed when cisplatin-induced apoptosis was measured by PARP cleavage (Fig. 2B). Interestingly, TR3 expression was induced by cisplatin in all 3 cell lines, including the cisplatin-resistant NCI/ADR-RES cells after 24-hour treatment (Fig. 2B). These results suggest that stimulation of TR3 expression alone is not sufficient for growth inhibition or apoptosis and other mechanisms play a role.

Mitochondrial targeting of TR3, leading to cytochrome c release, is associated with cisplatin-induced apoptosis in ovarian cancer cells

Cytotoxic drug-induced changes in the subcellular localization of TR3 have emerged as a primary mechanism for apoptosis induction. Previous studies have shown that various proapoptotic stimuli promote translocation of TR3 from the nucleus to the cytoplasm (5–11), often with direct mitochondrial targeting, and alters function of Bcl-2 to become proapoptotic (9). Therefore, we evaluated subcellular localization of TR3 before and after cisplatin treatment by immunofluorescence analyses. Consistent with previous reports (5–7), TR3 expression was predominantly localized to 4’, 6-diamidino-2-phenylindole (DAPI)-stained nuclei in untreated ovarian cancer cells (Fig. 2C). Cytoplasmic translocation of TR3 was significantly induced by cisplatin in OVCAR8 and OVCAR3 cells, but not in cisplatin-resistant NCI/ADR-RES cells (Fig. 2C and D). To determine mitochondrial localization, we showed that the punctate TR3 cytoplasmic staining pattern in cisplatin-treated cells

Published OnlineFirst May 29, 2013; DOI: 10.1158/0008-5472.CAN-12-4560
colocalized with the well-established mitochondrial marker, Hsp60 (Fig. 2C and E). To investigate the interaction between TR3 and Bcl-2, we conducted coimmunoprecipitation and immunofluorescence experiments and showed an association between TR3 and Bcl-2 in cisplatin-treated OVCAR8 cells (Fig. 2F).

To validate the possible link between cisplatin resistance and a lack of cisplatin-induced cytoplasmic targeting of TR3 in ovarian cancer cells, we used another well-characterized isogenic cell line model of cisplatin resistance in ovarian cancer, A2780 PAR and CP20 cells (26). As shown in Supplementary Fig. S5, there was a similar lack of TR3 mitochondrial targeting in cisplatin-treated CP20 cells compared with PAR cells. To link cytoplasmic TR3 translocation with apoptosis induction, we conducted immunofluorescence analyses of cytochrome c release. Cytochrome c is localized to the inner mitochondrial membrane in untreated cells and following stimulation with proapoptotic agents is released into the cytosol to form a diffuse staining pattern (6, 7). As shown in Fig. 2G and H, cisplatin-treated OVCAR8 and OVCAR3 cells displayed diffuse cytochrome c staining. The majority of the cells (>80%) simultaneously displayed cytoplasmic TR3 expression, implicating mitochondrial targeting of TR3 as a key factor in cytochrome c release and apoptosis. A small proportion of cells displayed cytochrome c release without mitochondrial TR3 targeting. Therefore, other mechanisms are likely to mediate cisplatin-induced apoptosis in these ovarian cancer cells.

To investigate TR3 in normal cells treated with cisplatin, we used HOSE ovarian epithelial cells as a model. We showed that in cisplatin-treated HOSE cells, TR3 expression is not only upregulated, but found in the cytoplasm, colocalized with mitochondrial Hsp60 (Supplementary Fig. S4).

**The nuclear export inhibitor leptomycin B reduces cisplatin-induced apoptosis and cytoplasmic targeting of TR3**

To better understand the link between mitochondrial targeting of TR3 and apoptosis in ovarian cancer cells, we conducted experiments with the well-established nuclear export inhibitor, leptomycin B (7). First, we confirmed that treatment of OVCAR8 cells with leptomycin B significantly reduced the number of cells showing cytoplasmic localization in immunofluorescence experiments (Fig. 3A). We validated these results with subcellular fractionation experiments (Fig. 3B). In cisplatin-treated cells where TR3 cytoplasmic translocation was inhibited, we observed a significant reduction in the number of cells showing cytochrome c release (Fig. 3C) and reduced levels of cleaved PARP and cleaved caspase-3 (Fig. 3D). Similar results were observed in OVCAR3...
cells (data not shown). We then tested the possibility that leptomycin B-mediated inhibition of apoptosis was due to reduced TR3 expression. However, cisplatin induced TR3 to a similar degree with and without leptomycin B pretreatment (Fig. 3D). These studies suggest that cytoplasmic TR3 translocation from the nucleus to the cytoplasm was essential for cisplatin-induced apoptosis in these ovarian cancer cells.

Ovarian cancer cells with TR3 downregulation are resistant to cisplatin-induced apoptosis in vitro and in vivo

Having established a functional link between TR3 and cisplatin-induced apoptosis, we next aimed to model the TR3 downregulation observed in ovarian tumors. To this end, we generated OVCAR8 cell clones stably transfected with shRNA-targeting TR3 (ShTR3) or control-scrambled shRNA (ShScr). We identified 3 GFP-positive clones displaying substantial TR3 downregulation at the protein level compared with control, scrambled shRNA (Fig. 4A and B). The highest levels of TR3 expression were observed in ShScr#1 cells, comparable with TR3 levels in parental OVCAR8 cells (data not shown). Showing the specificity of TR3 downregulation, protein expression of the structurally related NR4A family members, NR4A2/Nurr1 and NR4A3/Nor1, was not altered in these TR3 knockdown clones (Fig. 4A). A similar pattern of effect was observed at the mRNA level (Fig. 4C).

In SRB assays, ShTR3#3 cells showed significantly reduced basal growth compared with all 3 ShScr-expressing clones (Supplementary Fig. S6). Growth inhibition following TR3 knockdown was accompanied by upregulation of basal levels of the cyclin-dependent kinase inhibitor p21 (Fig. 4A). Notably, ShTR3#3 cells showed the highest p21 levels among the TR3 knockdown clones, consistent with the highest level of basal growth inhibition in these cells.

As shown in Supplementary Fig. S6, the inhibitory effects of 5 μmol/L cisplatin in ShScr clones in SRB assays were reduced in all 3 TR3 knockdown clones, with greatest inhibition observed in ShTR3#3 cells. Therefore, we selected the combination of ShScr#1 and ShTR3#3 cells for further analysis. We confirmed that cisplatin resistance in TR3 knockdown cells was observed over a range of cisplatin concentrations (2–10 μmol/L; Fig. 4D). Moreover, a major contribution to this effect in ShTR3 cells was inhibition of cisplatin-induced apoptosis, as evidenced by reduced levels of cleaved PARP and cleaved caspase-3 (Fig. 4E). We also

Figure 4. Cisplatin resistance in ovarian cancer cells with TR3 knockdown in vitro. A, protein levels of TR3 (NR4A1), NR4A2/Nurr1 and NR4A3/Nor1, and p21 in OVCAR-8 clones stably transfected with shRNA-targeting TR3 (ShTR3) or control-scrambled shRNA (ShScr). B, immunofluorescence analysis of GFP expression (green) and TR3 expression (red) in ShTR3#3 and ShScr#1 cells. DAPI-stained nuclei are in blue. C, quantitative RT-PCR analysis of TR3 and NR4A2 mRNA expression relative to corresponding GAPDH levels in ShTR3#3 cells compared with ShScr#1 cells. *, P < 0.01 relative to expression in ShScr control, Student's t test. D, effects of increasing concentrations of cisplatin in SRB assays (72-hour treatment). Values are the percentage growth inhibition by cisplatin in ShScr#1 and ShTR3#3 clones at each concentration tested. #, P < 0.01 relative to cisplatin effect in ShScr cells, Student's t test. Protein levels of TR3, cleaved PARP, and cleaved caspase-3 in ShTR3 and ShScr cells (E), and OVCAR3 cells (F) transiently transfected with NT or 2 distinct siRNAs targeting TR3 (siTR3), treated with 5 μmol/L cisplatin for 24 hours. All values are mean ± SD of 3 independent experiments.
confirmed that TR3 downregulation conferred resistance to cisplatin-induced apoptosis in OVCAR3 cells, using 2 distinct TR3-targeting siRNAs (Fig. 4F). Reduced cytoplasmic translocation of TR3 in ShTR3 and siTR3-transfected cells was confirmed by subcellular fractionation and immunofluorescence (data not shown).

The inhibitory effects of mechanistically distinct cytotoxic drugs, the DNA-damaging agent, doxorubicin, and the histone deacetylase inhibitor, SAHA, were also inhibited by TR3 knockdown in SRB assays (Supplementary Fig. S7A). We confirmed that doxorubicin and SAHA both induced mitochondrial targeting of TR3 in OVCAR8 cells (Supplementary Fig. S7B). These findings indicate that the reduced growth inhibitory and apoptotic effects following TR3 knockdown were not specific to cisplatin.

We next examined the response of ShScr#1 and ShTR3#3 cells to cisplatin in vivo. As shown in Fig. 5A–C, 3 weeks' treatment with cisplatin via intraperitoneal injection induced pronounced reduction in size of tumors derived from ShScr cells, an effect abrogated by approximately 52% ± 8% by TR3 knockdown. Basal growth of ShTR3 xenografts was reduced by 14% ± 5% compared with ShScr tumors, although this difference failed to reach statistical significance (P = 0.081, Mann-Whitney test). Immunohistochemical analyses were conducted to quantify the number of apoptotic and proliferating cells by staining for cleaved caspase-3 and Ki67, respectively. As shown in Fig. 5D and F, the cisplatin-induced increase in cleaved caspase-3 was significantly abrogated in ShTR3 cells. In contrast, the cisplatin-induced reduction in cells expressing Ki67 was similar between ShTR3 and control ShScr cells (Fig. 5E and F). These results suggest that reduced cisplatin-induced apoptosis in tumors with TR3 downregulation likely contributed more to cisplatin resistance than reduced growth-inhibitory effects.

Figure 5. Cisplatin resistance in TR3 knockdown cells in vivo. A, time course of growth of ShScr#1 and ShTR3#3 tumors in nude mice treated with vehicle (PBS) or cisplatin (5 mg/kg weekly) for 3 weeks. B, waterfall plot showing the percentage change in tumor volume from Time 0 (when drug injections were initiated) for individual tumors. Tumors are shown in C. Immunohistochemical analyses of expression of cleaved caspase-3 (D) and Ki67 (E). Values are mean ± SD; #, P < 0.01 relative to cisplatin effect in ShScr tumors, Student t test. F, high-power images for TR3, cleaved caspase-3, and Ki67 staining in vehicle- and cisplatin-treated tumors.
TR3 overexpression sensitizes ovarian cancer cells to cisplatin-induced apoptosis in vitro

As a large proportion of ovarian tumors retain high TR3 expression, which is associated with relative sensitivity to platinum chemotherapy, we next determined whether increasing TR3 expression increases response to cisplatin. We selected SKOV3 cells for these studies because of their relatively low endogenous TR3 protein expression (see Fig. 1A), which we confirmed in immunofluorescence experiments (data not shown). As shown in Fig. 6A, SKOV3 cells that were transiently transfected with a TR3-myc/DDK (FLAG)-tagged expression vector showed an increase in cisplatin sensitivity (see Fig. 1A), which we confirmed in coimmunoprecipitation experiments that OVCAR8 cells display increased levels of serine phosphorylation of TR3 (6) and protein levels of cleaved PARP and phospho-JNK (Thr183/Tyr185) in cisplatin-treated OVCAR8 cells (5 μmol/L; 24 hours; F). Effects of 2-hour pretreatment and cotreatment (3 hourly pulses) with the JNK activator anisomycin (Aniso; 25 ng/mL) and Akt inhibitor wortmannin (Wort; 5 μmol/L) on mitochondrial localization of TR3 (6) and protein levels of cleaved PARP, phospho-JNK (Thr183/Tyr185), and phospho-Akt (Ser473) in cisplatin-treated NCI/ADR-RES cells (5 μmol/L; 12 hours; H). All values are mean ± SD of 3 independent experiments. #, P < 0.01 relative to cisplatin alone. Student t test.

JNK and Akt mediate TR3 phosphorylation and nuclear export in association with cisplatin sensitivity in ovarian cancer cells

To investigate mechanisms linking nuclear export of TR3 to cisplatin sensitivity in ovarian cancer cells, we examined TR3 phosphorylation by JNK activation and Akt inhibition. It is known that N-terminal serine phosphorylation by JNK and loss of Akt-mediated phosphorylation on serine 351 are essential for nuclear export of TR3 (15). Furthermore, a less sustained JNK activation in cisplatin-resistant A2780 CP20 cells compared with PAR cells is observed following cisplatin treatment (34).

First, we showed JNK activation and AKT inhibition in OVCAR8 cells compared with cisplatin-resistant NCI/ADR-RES cells after 24-hour cisplatin treatment (Fig. 6C). Then, we showed in coimmunoprecipitation experiments that OVCAR8 cells display increased levels of serine phosphorylation of TR3 following cisplatin treatment, an effect not observed in NCI/ADR-RES cells (Fig. 6D). To directly test the role of JNK activation in cisplatin sensitivity, we treated OVCAR8 cells with the JNK-selective inhibitor SP600125 (35). When JNK was inhibited, cytoplasmic translocation and mitochondrial targeting of TR3 was reduced (Fig. 6E and F); effects were associated with reduced levels of cleaved PARP. Similar results were observed in cisplatin-treated OVCAR3 cells (Supplementary Fig. S8A and S8B).

Having established a role for JNK activation in cisplatin sensitivity, we asked whether cisplatin resistance could be overcome by the well-characterized JNK activator, anisomycin (36). Because inhibition of Akt is also necessary for TR3 nuclear export (15), we tested the effects of the Akt pathway inhibitor wortmannin (37). Treatment with anisomycin or wortmannin alone did not alter TR3 localization or apoptosis in cisplatin-
resistant NCI/ADR-RES cells (Supplementary Fig. S8). However, simultaneous treatment with wortmannin, anisomycin, and cisplatin in NCI/ADR-RES cells as shown in Fig. 6G and H, increased the number of cells with mitochondrial TR3 localization in association with apoptosis, and sensitized the cells to cisplatin-induced apoptosis. Similar results were seen in A2780 CP20 cells (Supplementary Fig. S8C and S8D).

Discussion

A clinical challenge in the treatment of metastatic ovarian cancer is the resistance to platinum-based chemotherapy. In this study, we show a role for TR3 in contributing to platinum-resistance in ovarian cancer. First, we show that low nuclear expression of TR3 is associated with platinum resistance and decreased survival in a large subset of metastatic serous ovarian cancers represented on a TMA we designed. Then, we show a role for TR3 in mediating chemotherapy-induced apoptosis in epithelial ovarian cancer cells. Finally, we identify 2 plausible mechanisms by which TR3 contributes to cisplatin resistance in ovarian cancer by: (i) downregulation of expression and (ii) aberrant nuclear sequestration.

To date, no previous reports have related protein expression of the TR3 nuclear orphan receptor in ovarian tumors to clinical outcomes. In our TMA, a large subset of metastatic ovarian serous tumors had low TR3 protein levels, which were associated with reduced responses to platinum chemotherapy, and decreased overall and PFS. TCGA data indicate that mRNA expression is not significantly different in platinum-resistant and -sensitive tumors, and show no significant association between TR3 expression and survival indices (3). Although limited by fewer cases, Yoshihara dataset reveals reduced PFS with low TR3 mRNA levels (33). Moreover, our results are consistent with previous reports of downregulated TR3 expression in other types of metastatic solid tumors (17, 20).

Targeting the proapoptotic effects of TR3 as a therapeutic tool is emerging as an attractive strategy for cancer treatment (4). In response to proapoptotic factors or direct agonists such as derivatives of cytosporone B and C-DIM (8, 16, 38), the TR3 orphan nuclear receptor is implicated in mediating apoptosis in cancer cells by at least three distinct mechanisms: (i) nucleus-to-cytoplasmic translocation, resulting in cytochrome c release through direct mitochondrial targeting of TR3 (5, 6, 8–11); (ii) mechanisms independent of mitochondrial association (7); and (iii) activation of TR3-mediated transcription (12–14). Although TR3 has been associated with vitamin K2-induced apoptosis in ovarian-derived teratocarcinoma Pa-1 cells (5), a role for TR3 in mediating chemotherapy-induced apoptosis in human ovarian cancer cells of epithelial origin has not been previously described. Here, we have identified nuclear export to the mitochondria as a major factor in determining cisplatin response in epithelial ovarian cancer cells.

Cytoplasmic translocation of TR3 was observed in relatively cisplatin-sensitive cells (OVCAR8, OVCAR3, and A2780 PAR), but not in cisplatin-resistant NCI/ADR-RES or A2780 CP20 cells. We show that TR3 is directly targeted to the mitochondria in ovarian cancer cells treated with cisplatin and other proapoptotic drugs, doxorubicin and the histone deacetylase inhibitor, SAHA. Moreover, several lines of evidence indicate that TR3 localized to the mitochondria is directly implicated in apoptosis induction. First, cytochrome c release was observed in approximately 80% of cells expressing cytoplasmic TR3. Second, inhibition of nuclear export of TR3 with leptotycin B significantly reduced the extent of cisplatin-induced apoptosis. Third, shRNA- and siRNA-mediated downregulation of TR3 expression resulted in significant resistance to the antitumor effects of cisplatin and other chemotherapeutic drugs, accompanied by reduced levels of TR3 in the cytoplasm. While these studies indicate a role for direct TR3-mediated activation of the intrinsic apoptotic pathway, the fact that leptotycin B did not completely inhibit cisplatin-induced apoptosis suggests that TR3 may also be exerting proapoptotic effects through in the nucleus. This result is consistent with the observed proapoptotic effects of the methylene-substituted diiodolymethane (C-DIM) family of TR3 agonists in cancer cells in the absence of cytoplasmic TR3 translocation (13, 38). To fully understand the role of TR3 in ovarian cancer apoptosis, we will explore nuclear TR3 proapoptotic effects in future studies.

We acknowledge that multiple alternative mechanisms of cisplatin-induced apoptosis and platinum resistance have been reported in cancer cells (39–44) that are TR3 independent. However, in this study, we have identified 2 mechanisms by which deregulation of TR3 function contributes to cisplatin resistance: downregulation of expression and aberrant nuclear sequestration. We also provide evidence that these effects may at least be partially overcome by TR3 overexpression or by stimulating TR3 phosphorylation and nuclear export by JNK activation and inhibition of Akt.

While reduced TR3 levels in advanced cancer may impair response to chemotherapy as suggested by our data, a study in breast cancer showed that downregulation of TR3 promotes cell invasion and migration (17). Therefore, TR3 may play a more complex role in ovarian cancer than simply as a putative target of therapy. Determining whether TR3 downregulation in ovarian cancer cells promotes other critical protumorigenic cellular processes, such as tumor cell invasion and/or activation of oncogenic signaling pathways (19), will be the focus of future studies. Adding to the complexity of the possible roles of TR3 in ovarian cancer, we also showed that there was reduced growth in TR3 knockdown cells. These findings suggest a proliferative role for TR3, which may have significance in some metastatic ovarian cancer cells and normal ovarian epithelial cells expressing high levels of TR3. Such a cell-type and context-dependent proliferative role for TR3 would be consistent with (i) the ability of mitogens to induce TR3 in the absence of apoptosis (7) and (ii) observations in various solid tumors, where TR3 is overexpressed in cancer cells compared with normal epithelium (16–19).

In conclusion, we have shown that TR3 is an important regulator of apoptosis and plays a role in mediating response to cytotoxic chemotherapy such as cisplatin in subtypes of ovarian cancer. Further investigation into cell-type and context-dependent mechanisms is planned. Nevertheless, our results suggest that targeting TR3 by activating its expression and promoting its nuclear export are rational therapeutic strategies for overcoming cisplatin resistance in ovarian cancer.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: A.J. Wilson, D. Khabele
Development of methodology: A.J. Wilson, D. Khabele
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): A.J. Wilson, J.T. Roland, J. Sasakiowski, M.A. Crispens, H.W. Jones III, S. James, O. Fadare, D. Khabele
Analysis and interpretation of data (e.g., statistical analysis, biosimulation, computational analysis): A.J. Wilson, J.T. Roland, O.B. Adebayo, S.A. Fletcher, J.C. Slaughter, D. Khabele
Writing, review, and/or revision of the manuscript: A.J. Wilson, J.C. Slaughter, J. Sasakiowski, D. Khabele
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): A.J. Wilson, A.Y. Liu, D. Khabele
Study supervision: D. Khabele

References

Acknowledgments
The authors thank the Vanderbilt University High-Throughput Screening Core, the Vanderbilt Immunohistochemistry Core, the Vanderbilt Genome Shared Resources Core, and the Vanderbilt Epithelial Biology Center Core. The authors also thank Ms. Lynne Black for administrative and editorial support.

Grant Support
This work was supported by the National Center for Research Resources, Grant U1L RR02975-01, and is now at the National Center for Advancing Translational Sciences, Grant 2UL1 TR000445-06. A.J. Wilson was also supported by the Marsha Rivkin Ovarian Cancer Foundation. D. Khabele was supported by NIH grants S50 CA106294, S10RR02975, and K08CA119887-01.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received December 13, 2012; revised April 16, 2013; accepted May 6, 2013; published OnlineFirst May 29, 2013.
37. Whitley BR, Beaulieu LM, Carter JC, Church FC. Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells. Gynecol Oncol 2007;104:470–9.
TR3 Modulates Platinum Resistance in Ovarian Cancer

Andrew J. Wilson, Annie Y. Liu, Joseph Roland, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-12-4560

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2013/05/28/0008-5472.CAN-12-4560.DC1

Cited articles
This article cites 44 articles, 21 of which you can access for free at:
http://cancerres.aacrjournals.org/content/73/15/4758.full#ref-list-1

Citing articles
This article has been cited by 2 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/73/15/4758.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.